title: 18-month effectiveness of short-course antiretroviral regimens combined with alternatives to breastfeeding to prevent HIV mother-to-child transmission.
abstract: OBJECTIVE
  We assessed the 18-month effectiveness of short-course (sc) antiretroviral peripartum regimens combined with alternatives to prolonged breastfeeding to prevent mother-to-child transmission (MTCT) of HIV-1 in Abidjan, Côte d'Ivoire.
  
  
  METHODS
  HIV-1 infected pregnant women received from >/=32-36 weeks of gestation scZidovudine (ZDV)+/-Lamivudine (3TC)+single-dose Nevirapine (sdNVP) at delivery within the ANRS 1201/1202 DITRAME-Plus cohort (2001-2003). Neonates received a sdNVP+7-day ZDV prophylaxis. Two infant-feeding interventions were systematically offered free of charge: formula-feeding or exclusive shortened breastfeeding with early cessation from four months. The reference group was the ANRS 049a DITRAME cohort (1994-2000) exposed to scZDV from 36 weeks, then to prolonged breastfeeding. Pediatric HIV infection was defined by a positive plasma HIV-1 RNA at any age, or if aged >/=18 months, a positive HIV-1 serology. Turnbull estimates of cumulative transmission risks (CTR) and effectiveness (HIV-free survival) were compared by exposure group using a Cox model.
  
  
  RESULTS
  Among 926 live-born children enrolled, 107 (11.6%) were HIV-infected at 18 months. CTRs were 22.3% (95% confidence interval[CI]:16-30%) in the 238 ZDV long-term breastfed reference group, 15.9% (CI:10-27%) in the 169 ZDV+sdNVP shortened breastfed group; 9.4% (CI:6-14%) in the 195 ZDV+sdNVP formula-fed group; 6.8% (CI:4-11%) in the 198 ZDV+3TC+sdNVP shortened breastfed group, and 5.6% (CI:2-10%) in the 126 ZDV+3TC+sdNVP formula-fed group. Each combination had a significantly higher effectiveness than the ZDV long-term breastfed group except for ZDV+sdNVP shortened breastfed children, ranging from 51% (CI:20-70%) for ZDV+sdNVP formula fed children to 63% (CI:40-80%) for ZDV+3TC+NVPsd shortened breastfed children, after adjustment for maternal eligibility for antiretroviral therapy (ART), home delivery and low birth-weight. Substantial MTCT risk reductions are reachable in Africa, even in short-term breastfed children. The two sc antiretroviral combinations associated to any of the two infant feeding interventions, formula-feeding and shortened breastfeeding, reduce significantly MTCT with long-term benefit until age 18 months and without increasing mortality.
authors.affiliation: French National Institute for Health and Medical Research (INSERM), Unité 897, Centre de recherche "Epidémiologie et Biostatistique", Bordeaux, France. valeriane.leroy@isped.u-bordeaux2.fr
authors.forename: Valériane
authors.initials: V
authors.lastname: Leroy
authors.forename: Didier K
authors.initials: DK
authors.lastname: Ekouevi
authors.forename: Renaud
authors.initials: R
authors.lastname: Becquet
authors.forename: Ida
authors.initials: I
authors.lastname: Viho
authors.forename: Laurence
authors.initials: L
authors.lastname: Dequae-Merchadou
authors.forename: Besigin
authors.initials: B
authors.lastname: Tonwe-Gold
authors.forename: François
authors.initials: F
authors.lastname: Rouet
authors.forename: Charlotte
authors.initials: C
authors.lastname: Sakarovitch
authors.forename: Appolinaire
authors.initials: A
authors.lastname: Horo
authors.forename: Marguerite
authors.initials: M
authors.lastname: Timité-Konan
authors.forename: Christine
authors.initials: C
authors.lastname: Rouzioux
authors.forename: François
authors.initials: F
authors.lastname: Dabis
mesh_terms: D000349:Africa; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D001942:Breast Feeding; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000401:mortality / Q000517:prevention & control* / Q000635:transmission; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D019259:Lamivudine; D019829:Nevirapine; D016016:Proportional Hazards Models; D015996:Survival Rate; D016896:Treatment Outcome; D015215:Zidovudine
chemical_list: D019380:Anti-HIV Agents; D019259:Lamivudine; D015215:Zidovudine; D019829:Nevirapine